With this rebranding, Ascenion’s portfolio company aims to extend its existing expertise in the field of AI-supported medical devices to additional areas of application within hospitals. The focus is on the Clé platform, which is designed to enable hospitals to make confident use of modern language models and agent-based AI. The platform can be…
sThesis, together with its partners Helmholtz Munich, TUM University Hospital Rechts der Isar and LMU Hospital Munich, successfully competed in a Europe-wide competition organized by the German Federal Agency for Breakthrough Innovation (SPRIND). A total of 68 teams applied. Under the project title ‘Non-invasive Continuous Endocrine Phenotyping’,…
[Click here to Download]
[Click here to Download]
[Click here to Download]
[Click here to Download]
[Click here to Download]
[Click here to Download]
[Click here to Download]
[Click here to Download]
[Click here to Download]
Digital Technology Transfer Academy
Ascenion’s Life Science Digital Hub: A GO-Bio initial…
Webinars
Webinars
Ascenion’s Life Science Digital Hub: A GO-Bio initial module
With our Life Science Digital Hub program we want to support young researchers on their journey to bring their ideas to the market. We offer assistance during the application process for the GO-Bio initial funding of the German Federal Ministry of…
Contact
Dr Rebecca Engels Project Manager GO-Bio initial T: +49 89 318814-38 engels@ascenion.de
The Life Science Digital Hub project is funded by the German Federal Ministry of Education and Research as part of the GO-Bio initial program.
Funding reference: 16LW0585
Want to keep your fingers on the pulse of academic…
Under the S3LTEC brand, PROVIREX operates Germany’s first S3**-GMP cleanroom production facility, supporting both the advancement of its genome editing platform for HIV and the contract manufacturing of CAR-T cells. The new site at tecHHub Hamburg offers 400 m² of laboratory space, including 230 m² of cleanroom facilities spanning classes A to D,…
The Berlin-based biotech company is developing OMT-28 for the treatment of Primary Mitochondrial Diseases (PMD). These rare genetic metabolic disorders can severely limit physical performance and may damage the heart, skeletal muscles and nervous system. At present, no FDA-approved therapy is available for the vast majority of affected patients.…
The PROTON team, led by Prof. Mark Brönstrup, has been nominated for the development of a novel antibiotic technology to combat Staphylococcus aureus. The approach does not aim to inhibit bacterial growth, but rather blocks disease-causing mechanisms. The focus is on a pathoblocker targeting a toxin that damages lung tissue and immune cells. The…
Helmholtz Munich together with University Hospital Münster (UKM) and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, have announced updated preliminary results from their joint Phase I clinical trial of investigational candidate ITM-31 in patients with glioblastoma.
The investigator-initiated Phase I…
Ascenion, mit Firmenhauptsitz in München, ist ein Tochterunternehmen der LifeScience-Stiftung zur Förderung von Wissenschaft und Forschung und Technologietransferpartner von über 30 öffentlichen Forschungseinrichtungen und Universitätskliniken. Wir identifizieren kommerziell aussichtsreiche Forschungsergebnisse, organisieren den patentrechtlichen…
Since late 2024, Mario has been working in Munich for two venture capital firms, Gimv and OCCIDENT. His work focused on the scientific, economic and financial evaluation of investment opportunities in biotech, medtech and diagnostics companies, as well as conducting due diligence processes and analysing deal flow, markets and competition. In…
BioVaria
Where science and industry meet
Each year, BioVaria brings together leading figures from European science, technology and industry for two interactive days in Munich. Their common goal: to initiate partnerships that transfer particularly promising projects from European academic life-science research into application: new diagnositic…
The German Spin-off Framework (GSOF) is a voluntary commitment by numerous stakeholders in the innovation ecosystem to adopt common standards for research-based spin-offs and has already garnered 44 supporters in its first iteration. The framework aims to reduce friction and increase transparency by establishing practical “landing zones” for…
